Xiong Jing, Guo Jianxin, Huang Luosheng, Meng Boyu, Ping Qineng
Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, PR China.
Int J Pharm. 2008 Aug 6;360(1-2):191-6. doi: 10.1016/j.ijpharm.2008.04.016. Epub 2008 Apr 16.
The purpose of this research is to evaluate the effect of self-micelle formation and incorporation of lipid in the formulation on absorption of ginsenosides Rg1 and Rb1 from intestinal tract in rats. Ginsenosides Rg1 and Rb1 were extracted from Panax notoginseng saponins (PNS). The critical micellar concentration (CMC) of PNS in deionzied water was determined to be 0.339 mg/ml. At normal physiological ionic strengths, PNS was salted out from the solution above the CMC. The particle size of the micelle grows as PNS concentration increases. By in situ injection to a closed loop of the rat jejunum, AUC0-6h obtained after administration of low concentration solution (12 mg/ml) was 3.61 times for ginsenoside Rg1 and 3.84-folds for ginsenoside Rb1 compared with high concentration solution (120 mg/ml). The release rate of ginsenosides in aqueous medium was too slow to complete in 24h, especially for Rb1. The data suggested that the self-micelle formation tendency in ginsenosides might prevent them from permeation or absorption through the cell membrane of gastrointestinal (GI) tract. To inhibit the formation of micelles, lipid was incorporated in the PNS formulation. The intraduodenal bioavailability in rats showed that the bioavailability was enhanced remarkably relative to the aqueous solution. AUC 0-infinity of ginsenoside Rg1 and Rb1 in the lipid-based formulation were 207.52+/-53.95 and 1961.72+/-686.60 microg ml(-1) h, compared with 7.87+/-2.85 and 148.58+/-36.73 microg ml(-1) h, respectively from its aqueous solution. These findings suggested a new strategy to increase the absorption of amphiphilic saponins.
本研究的目的是评估制剂中自微乳形成及脂质掺入对大鼠肠道中人参皂苷Rg1和Rb1吸收的影响。人参皂苷Rg1和Rb1从三七总皂苷(PNS)中提取。测定PNS在去离子水中的临界胶束浓度(CMC)为0.339 mg/ml。在正常生理离子强度下,高于CMC时PNS会从溶液中盐析出来。随着PNS浓度增加,胶束粒径增大。通过原位注射到大鼠空肠的闭合肠袢中,低浓度溶液(12 mg/ml)给药后获得的AUC0-6h,人参皂苷Rg1是高浓度溶液(120 mg/ml)的3.61倍,人参皂苷Rb1是其3.84倍。人参皂苷在水介质中的释放速率过慢,24小时内无法完全释放,尤其是Rb1。数据表明人参皂苷中的自微乳形成趋势可能会阻止它们透过胃肠道(GI)细胞膜进行渗透或吸收。为抑制胶束形成,在PNS制剂中掺入脂质。大鼠十二指肠内生物利用度表明,相对于水溶液,生物利用度显著提高。脂质基制剂中人参皂苷Rg1和Rb1的AUC 0-∞分别为207.52±53.95和1961.72±686.60 μg ml(-1) h,而其水溶液分别为7.87±2.85和148.58±36.73 μg ml(-1) h。这些发现提示了一种提高两亲性皂苷吸收的新策略。